Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liquid Biopsy Monitoring in Gastric Cancer Neoadjuvant Chemotherapy
NCT03957564Phase 2Unknown
- Sponsor
- Affiliated Hospital of Qinghai University
- Start
- May 2019
- Primary completion
- May 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, oxaliplatin and tegafur in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by Affiliated Hospital of Qinghai University. Primary endpoints: Numbers of CTC pre- and post- neoadjuvant chemotherapy and after operation at 2 years, Types of CTC pre- and post- neoadjuvant chemotherapy and after operation at 2 years and 4 more. Status: unknown.
02
Drugs
paclitaxeloxaliplatintegafur
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03957564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957564.